These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 28182994)

  • 21. Modulation of hypersensitivity to oxidative DNA damage in ATM defective cells induced by potassium bromate by inhibition of the Poly (ADP-ribose) polymerase (PARP).
    Mosesso P; Piane M; Pepe G; Cinelli S; Chessa L
    Mutat Res Genet Toxicol Environ Mutagen; 2018 Dec; 836(Pt A):117-123. PubMed ID: 30389154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer.
    Papageorgiou GI; Fergadis E; Skouteris N; Christakos E; Tsakatikas SA; Lianos E; Kosmas C
    Front Oncol; 2021; 11():788809. PubMed ID: 35004311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP
    Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Testosterone promotes DNA damage response under oxidative stress in prostate cancer cell lines.
    Ide H; Lu Y; Yu J; China T; Kumamoto T; Koseki T; Yamaguchi R; Muto S; Horie S
    Prostate; 2012 Sep; 72(13):1407-11. PubMed ID: 22290195
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition.
    Aguilar-Quesada R; Muñoz-Gámez JA; Martín-Oliva D; Peralta A; Valenzuela MT; Matínez-Romero R; Quiles-Pérez R; Menissier-de Murcia J; de Murcia G; Ruiz de Almodóvar M; Oliver FJ
    BMC Mol Biol; 2007 Apr; 8():29. PubMed ID: 17459151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
    J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
    Parkes EE; Kennedy RD
    Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells.
    Minami D; Takigawa N; Takeda H; Takata M; Ochi N; Ichihara E; Hisamoto A; Hotta K; Tanimoto M; Kiura K
    Mol Cancer Res; 2013 Feb; 11(2):140-8. PubMed ID: 23239809
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of ATM with KU-55933 Sensitizes Endometrial Cancer Cell Lines to Olaparib.
    Zhang A; Zhang L; Xie X; Liu D
    Onco Targets Ther; 2023; 16():1061-1071. PubMed ID: 38144904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relevance of ATM Status in Driving Sensitivity to DNA Damage Response Inhibitors in Patient-Derived Xenograft Models.
    Karmokar A; Sargeant R; Hughes AM; Baakza H; Wilson Z; Talbot S; Bloomfield S; Leo E; Jones GN; Likhatcheva M; Tobalina L; Dean E; Cadogan EB; Lau A
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Poly(ADP-ribose) polymerase-1 inhibits ATM kinase activity in DNA damage response.
    Watanabe F; Fukazawa H; Masutani M; Suzuki H; Teraoka H; Mizutani S; Uehara Y
    Biochem Biophys Res Commun; 2004 Jun; 319(2):596-602. PubMed ID: 15178448
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly(ADP-ribose) polymerase activity is not affected in ataxia telangiectasia cells and knockout mice.
    Dantzer F; Ménissier-de Murcia J; Barlow C; Wynshaw-Boris A; de Murcia G
    Carcinogenesis; 1999 Jan; 20(1):177-80. PubMed ID: 9934867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells.
    Shimo T; Kurebayashi J; Kanomata N; Yamashita T; Kozuka Y; Moriya T; Sonoo H
    Breast Cancer; 2014 Jan; 21(1):75-85. PubMed ID: 22454224
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
    Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
    Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA damage sensors ATM, ATR, DNA-PKcs, and PARP-1 are dispensable for human immunodeficiency virus type 1 integration.
    Ariumi Y; Turelli P; Masutani M; Trono D
    J Virol; 2005 Mar; 79(5):2973-8. PubMed ID: 15709017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy.
    Bian X; Gao J; Luo F; Rui C; Zheng T; Wang D; Wang Y; Roberts TM; Liu P; Zhao JJ; Cheng H
    Oncogene; 2018 Jan; 37(3):341-351. PubMed ID: 28945226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib.
    Ali R; Alblihy A; Toss MS; Algethami M; Al Sunni R; Green AR; Rakha EA; Madhusudan S
    Ther Adv Med Oncol; 2020; 12():1758835920974201. PubMed ID: 33425022
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes.
    Wang D; Li C; Zhang Y; Wang M; Jiang N; Xiang L; Li T; Roberts TM; Zhao JJ; Cheng H; Liu P
    Gynecol Oncol; 2016 Sep; 142(3):548-56. PubMed ID: 27426307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.